Zolinza News and Research

RSS
Zolinza is a drug that is used to treat cutaneous T-cell lymphoma that does not get better, gets worse, or comes back during or after treatment with other drugs. It is also being studied in the treatment of other types of cancer. Zolinza is a type of histone deacetylase inhibitor. Also called SAHA, suberoylanilide hydroxamic acid, and vorinostat.
Pre-existing anticancer drug could help treat common form of heart failure

Pre-existing anticancer drug could help treat common form of heart failure

Researchers develop new drug-testing platform for epilepsy

Researchers develop new drug-testing platform for epilepsy

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

Arno AR-42 for neurofibromatosis type 2 receives EMA orphan-drug designation

Arno AR-42 for neurofibromatosis type 2 receives EMA orphan-drug designation

FDA grants orphan-drug designation to Arno's AR-42 for treatment of meningioma, schwannoma

FDA grants orphan-drug designation to Arno's AR-42 for treatment of meningioma, schwannoma

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Vorinostat in addition to chemotherapy drugs improves remission rates in AML patients

Vorinostat in addition to chemotherapy drugs improves remission rates in AML patients

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck receives FDA approval for redesigned drug container labels

Merck receives FDA approval for redesigned drug container labels

Arno Therapeutics closes private placement to advance cancer treatment

Arno Therapeutics closes private placement to advance cancer treatment

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

Merck hosts R&D and Business Briefing

Merck hosts R&D and Business Briefing

Decision Resources forecasts multiple myeloma drug market to more than double from $2.1B in 2008 to $5.3B in 2018

Decision Resources forecasts multiple myeloma drug market to more than double from $2.1B in 2008 to $5.3B in 2018

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

FDA approves Istodax for treatment of Cutaneous T-cell Lymphoma

FDA approves Istodax for treatment of Cutaneous T-cell Lymphoma

Merck's sales increases by 2% in third quarter 2009

Merck's sales increases by 2% in third quarter 2009

New data on ZOLINZA (vorinostat) in combination with Bortezomib

New data on ZOLINZA (vorinostat) in combination with Bortezomib

Scientists synthesize promising anti-cancer product from marine algae

Scientists synthesize promising anti-cancer product from marine algae

Study results from Zolinza (vorinostat) in combination with bortezomib for multiple myeloma trial

Study results from Zolinza (vorinostat) in combination with bortezomib for multiple myeloma trial